A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the progression free survival of LY2510924 +
carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with
extensive-stage disease small cell lung cancer (SCLC)